Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Specialty — Commercial operations and salesforce

Similar metrics at other companies

CONMED logo
CNMDSalesforce and commission expense
$59.15M+0.4%
Associated Banc-Corp logo
ASBCorporate and Commercial Specialty — Commercial and business lending
$18.81B+8.1%
Associated Banc-Corp logo
ASBCorporate and Commercial Specialty — Goodwill
$525.84M0.0%
Associated Banc-Corp logo
ASBCorporate and Commercial Specialty — Interest Income (Expense), Operating
$231.11M+1.7%
Associated Banc-Corp logo
ASBCorporate and Commercial Specialty — Intangible Amortization
$0
Associated Banc-Corp logo
ASBCorporate and Commercial Specialty — Total Assets
$19.57B+10.7%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept amrx:CommercialOperationsAndSalesforceExpense.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Employee compensation and benefits$12,938$10,791$24,873$21,663
Product marketing13,9919,88421,80817,895
Commercial operations and salesforce11,6028,78725,37519,578
Other (1)1,5648522,7302,156
Total$40,095$30,314$74,786$61,292

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s specialty — commercial operations and salesforce?
Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — commercial operations and salesforce of $11.6M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s specialty — commercial operations and salesforce changed year-over-year?
Amneal Pharmaceuticals, Inc.'s specialty — commercial operations and salesforce increased by 32.0% year-over-year, from $8.79M to $11.6M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — commercial operations and salesforce?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — commercial operations and salesforce has grown at a 29.8% compound annual growth rate (CAGR), from $20.26M to $44.3M.
What does specialty — commercial operations and salesforce mean?
Covers the costs associated with maintaining the sales infrastructure and commercial teams responsible for distributing specialty products. This metric tracks the efficiency of the sales organization in converting product availability into revenue.

Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — commercial operations and salesforce.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude